227 related articles for article (PubMed ID: 20547681)
1. Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness in the active period of the diurnal cycle.
Li A; Nattie E
J Physiol; 2010 Aug; 588(Pt 15):2935-44. PubMed ID: 20547681
[TBL] [Abstract][Full Text] [Related]
2. The orexin receptor 1 (OX1R) in the rostral medullary raphe contributes to the hypercapnic chemoreflex in wakefulness, during the active period of the diurnal cycle.
Dias MB; Li A; Nattie E
Respir Physiol Neurobiol; 2010 Jan; 170(1):96-102. PubMed ID: 19995618
[TBL] [Abstract][Full Text] [Related]
3. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.
Mang GM; Dürst T; Bürki H; Imobersteg S; Abramowski D; Schuepbach E; Hoyer D; Fendt M; Gee CE
Sleep; 2012 Dec; 35(12):1625-35. PubMed ID: 23204605
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of orexin receptor-1 in the retrotrapezoid nucleus inhibits the ventilatory response to hypercapnia predominantly in wakefulness.
Dias MB; Li A; Nattie EE
J Physiol; 2009 May; 587(Pt 9):2059-67. PubMed ID: 19273574
[TBL] [Abstract][Full Text] [Related]
5. The brain orexin system and almorexant in fear-conditioned startle reactions in the rat.
Steiner MA; Lecourt H; Jenck F
Psychopharmacology (Berl); 2012 Oct; 223(4):465-75. PubMed ID: 22592903
[TBL] [Abstract][Full Text] [Related]
6. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat.
Dugovic C; Shelton JE; Aluisio LE; Fraser IC; Jiang X; Sutton SW; Bonaventure P; Yun S; Li X; Lord B; Dvorak CA; Carruthers NI; Lovenberg TW
J Pharmacol Exp Ther; 2009 Jul; 330(1):142-51. PubMed ID: 19363060
[TBL] [Abstract][Full Text] [Related]
7. Blockade of orexin receptors with Almorexant reduces cardiorespiratory responses evoked from the hypothalamus but not baro- or chemoreceptor reflex responses.
Iigaya K; Horiuchi J; McDowall LM; Lam AC; Sediqi Y; Polson JW; Carrive P; Dampney RA
Am J Physiol Regul Integr Comp Physiol; 2012 Nov; 303(10):R1011-22. PubMed ID: 23019212
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.
Malherbe P; Borroni E; Pinard E; Wettstein JG; Knoflach F
Mol Pharmacol; 2009 Sep; 76(3):618-31. PubMed ID: 19542319
[TBL] [Abstract][Full Text] [Related]
9. Examining the role of endogenous orexins in hypothalamus-pituitary-adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat.
Steiner MA; Sciarretta C; Brisbare-Roch C; Strasser DS; Studer R; Jenck F
Psychoneuroendocrinology; 2013 Apr; 38(4):560-71. PubMed ID: 22917622
[TBL] [Abstract][Full Text] [Related]
10. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep.
Mieda M; Hasegawa E; Kisanuki YY; Sinton CM; Yanagisawa M; Sakurai T
J Neurosci; 2011 Apr; 31(17):6518-26. PubMed ID: 21525292
[TBL] [Abstract][Full Text] [Related]
11. Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA).
Malherbe P; Roche O; Marcuz A; Kratzeisen C; Wettstein JG; Bissantz C
Mol Pharmacol; 2010 Jul; 78(1):81-93. PubMed ID: 20404073
[TBL] [Abstract][Full Text] [Related]
12. State-dependent central chemoreception: a role of orexin.
Kuwaki T; Li A; Nattie E
Respir Physiol Neurobiol; 2010 Oct; 173(3):223-9. PubMed ID: 20170755
[TBL] [Abstract][Full Text] [Related]
13. Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleep.
Kummangal BA; Kumar D; Mallick HN
Behav Brain Res; 2013 Jan; 237():59-62. PubMed ID: 22989413
[TBL] [Abstract][Full Text] [Related]
14. The dual orexin/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration.
Srinivasan S; Simms JA; Nielsen CK; Lieske SP; Bito-Onon JJ; Yi H; Hopf FW; Bonci A; Bartlett SE
PLoS One; 2012; 7(9):e44726. PubMed ID: 23028593
[TBL] [Abstract][Full Text] [Related]
15. Histamine-1 receptor is not required as a downstream effector of orexin-2 receptor in maintenance of basal sleep/wake states.
Hondo M; Nagai K; Ohno K; Kisanuki Y; Willie JT; Watanabe T; Yanagisawa M; Sakurai T
Acta Physiol (Oxf); 2010 Mar; 198(3):287-94. PubMed ID: 19694625
[TBL] [Abstract][Full Text] [Related]
16. Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant.
Dietrich H; Jenck F
Psychopharmacology (Berl); 2010 Oct; 212(2):145-54. PubMed ID: 20631993
[TBL] [Abstract][Full Text] [Related]
17. Orexin Receptor Antagonism Improves Sleep and Reduces Seizures in Kcna1-null Mice.
Roundtree HM; Simeone TA; Johnson C; Matthews SA; Samson KK; Simeone KA
Sleep; 2016 Feb; 39(2):357-68. PubMed ID: 26446112
[TBL] [Abstract][Full Text] [Related]
18. Role of orexin input in the diurnal rhythm of locus coeruleus impulse activity.
Gompf HS; Aston-Jones G
Brain Res; 2008 Aug; 1224():43-52. PubMed ID: 18614159
[TBL] [Abstract][Full Text] [Related]
19. Locus Coeruleus and Tuberomammillary Nuclei Ablations Attenuate Hypocretin/Orexin Antagonist-Mediated REM Sleep.
Schwartz MD; Nguyen AT; Warrier DR; Palmerston JB; Thomas AM; Morairty SR; Neylan TC; Kilduff TS
eNeuro; 2016; 3(2):. PubMed ID: 27022631
[TBL] [Abstract][Full Text] [Related]
20. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
